Chemical shift assignments of the partially deuterated Fyn SH2–SH3 domain by Kieken, Fabien et al.
UN
CO
RR
EC
TE
D P
RO
OF
Journal : Large 12104 Article No : 9792 Pages : 6 MS Code : BNMR-D-17-00036 Dispatch : 28-11-2017
Vol.:(0123456789) 
Biomolecular NMR Assignments 
https://doi.org/10.1007/s12104-017-9792-1
ARTICLE
Chemical shift assignments of the partially deuterated Fyn SH2–SH3 
domain
Fabien Kieken1,2,3 · Karine Loth4,5 · Nico van Nuland1,2 · Peter Tompa1,2 · Tom Lenaerts3,6,7 
Received: 3 July 2017 / Accepted: 28 November 2017 
© Springer Science+Business Media B.V., part of Springer Nature 2017
Abstract
Src Homology 2 and 3 (SH2 and SH3) are two key protein interaction modules involved in regulating the activity of many 
proteins such as tyrosine kinases and phosphatases by respective recognition of phosphotyrosine and proline-rich regions. In 
the Src family kinases, the inactive state of the protein is the direct result of the interaction of the SH2 and the SH3 domain 
with intra-molecular regions, leading to a closed structure incompetent with substrate modification. Here, we report the 1H, 
15N and 13C backbone- and side-chain chemical shift assignments of the partially deuterated Fyn SH3–SH2 domain and 
structural differences between tandem and single domains. The BMRB accession number is 27165.
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Biological context
The Src family consists of 11 non-receptor tyrosine kinases 
involved in a plethora of fundamental biological processes 
including cell growth, differentiation, cellular adhesion, cell 
migration (Manning et al. 2002). The structural organization 
of each family member is equivalent: They are composed of 
four different domains—SH1 to SH4—with a C-terminal 
negative regulatory tail. The SH4 domain located in the 
N-terminus anchors the proteins to the plasma membrane 
and is attributed with the varying physiological functions 
of the family members (Sato et al. 2009). SH3 and SH2 
domains are involved in regulating kinase activity and medi-
ate the interaction of the kinase with its protein partners, and 
SH1 is the kinase domain (Boggon and Eck 2004; Sicheri 
and Kuriyan 1997). Src family kinases (SFK) catalytic activ-
ity is determined by intermolecular interactions and equilib-
rium of phosphorylation-dephosphorylation states. Activa-
tion of the kinase is triggered by the dephosphorylation of 
the phospho-tyrosine in the C-terminus, which in turn results 
in the initiation of signaling cascades that drive basic cel-
lular function (Huculeci et al. 2016; Xu et al. 1999). Given 
their important role in fundamental physiological and patho-
logical processes, members of the SFK have been widely 
investigated in various biological contexts.
Fyn, one of the SFK members, regulates numerous cel-
lular processes including motility, growth, differentiation 
and signal transduction in various cell types (Saito et al. 
2010). The Fyn gene has three splice variants, one of which 
is deemed inactive. FynT is highly expressed in cells of 
hematopoietic lineage and regulates immune cell functions 
and inflammatory responses. The other active form FynB 
is ubiquitous, with the highest expression in the synaptic 
architecture of the central nervous system, playing impor-
tant roles in glutamate receptor trafficking and synaptic 
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plasticity (Grant et al. 1992; Kojima et al. 1998; Nakazawa 
et al. 2001; Prybylowski et al. 2005; Suzuki and Okumura-
Noji 1995). Beyond it’s basic physiological functions, Fyn 
has been widely investigated as a therapeutic target due to 
its implication in the pathophysiology of various cancers, 
neurodegenerative and psychiatric diseases (Nygaard et al. 
2014; Ohnuma et al. 2003; Panicker et al. 2015). Fyn has 
been found significantly upregulated in cancer tissues, with 
its level correlating with aggressive disease progression and 
metastasis [review (Elias and Ditzel 2015)], which results 
from promoting cancer cell proliferation and inhibition of 
cell death (Elias et al. 2015; Li et al. 2003). Inhibition of Fyn 
function is thought to have therapeutic potential in cancer 
and neurodegenerative conditions. Various inhibitors of Fyn 
kinase domain are available; however these carry various 
safety liabilities and long term toxicity due to lack of speci-
ficity in inhibiting kinase functions (Grant 2009).
Fyn’s SH1 activity is regulated by the intramolecular 
interactions with two of its domains, SH3 and SH2. SH3 
domains interact primarily with sequences rich in proline, 
such as PxxP motifs, although they can also bind other 
sequences that deviate from the canonical one [review (Sak-
sela and Permi 2012)], whereas SH2 domains recognize and 
bind phosphotyrosine residues (Pawson 1995). Fyn SH2 is 
responsible for the state of activation of the kinase. Phos-
phorylated Tyr527 allows a direct interaction between Fyn 
SH2 with the C-terminus, resulting in an inactive kinase 
state. The kinase self-activation occurs during the dephos-
phorylation of Tyr527 and/or the binding of protein partners, 
allowing the dissociation between SH3, SH2, and the kinase 
domain [review in (Roskoski 2015)].
The mechanism of propagation of the information or 
cross-communication between the two domains is not well 
investigated and has led to controversial reports. While the 
SH3 domain enhances Fyn SH2-mediated ligand binding 
(Panchamoorthy et al. 1994) and the replacement of the 
SH3–SH2 linker residues with glycines activates c-Src 
(Young et al. 2001), the analysis of the dynamics of Fyn 
SH3–SH2 by nuclear magnetic resonance (NMR)  T1/T2/
NOE, domain alignment by residual dipolar couplings 
and crystallographic structure showed very little structural 
modifications (Ulmer et al. 2002). Nonetheless, recent work 
showed that sidechain dynamics plays a role in the activation 
process (Huculeci et al. 2016).
As no solution structure by NMR of human wild type Fyn 
SH3–SH2 is available, we report here on the full backbone 
and side-chain 1H, 15N and 13C assignment of partially deu-
terated 13C, 15N-labeled Fyn SH3–SH2 in its free form using 
high-resolution NMR techniques. The anticipated structural 
resolution of the tandem domains by NMR will provide 
additional information on changes of structure and dynam-
ics between domains, hopefully providing an explanation 
for the mechanism of information propagation throughout 
the structure.
Methods and experiments
Protein expression and purification
The human Fyn SH3–SH2 domain (residues 82–248), SH3 
domain (82–147) and SH2 domain (148–248) were sub-
cloned into a pet15b (Novagen) vector containing a throm-
bin-cleavable N-terminal hexa-His tag by standard cloning 
methods.
Transformed BL21(DE3)star cells (Invitrogen) were 
grown at 37 °C in 1 L of minimal medium implemented with 
0.75 g 15NH4Cl and 2 g 13C-glucose (Cambridge Isotope 
Laboratories). The bacteria were induced at a cell density of 
0.6 by addition of 0.5 mM IPTG and were then incubated at 
22 °C overnight. The cells were pelleted by centrifugation at 
7000×g and the pellet kept and stored at − 80 °C for further 
processing. The expression of the partially deuterated and 
uniformly 13C/15N-labeled protein was achieved by making 
the minimal medium 60% in  D2O (Cortecnet) complemented 
with 0.75 g 15NH4Cl and 2 g 13C-glucose.
The pellets were thawn and resuspended in lysis buffer 
(20 mM Hepes pH 7.6, 100 mM  Na2SO4, 20 mM imidazole, 
10 mM β-mercaptoethanol (BME), 10% glycerol containing 
0.2 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochlo-
ride (AEBSF), 5 μg/mL leupeptin and 4 units/mL of DNAse 
I). The cells were lysed by sonication using a Sonics Vibra-
CellTM CV18 model ultrasonic processor (70% amplitude, 
3 s pulse on/off for 10 min) and the lysates were centrifuged 
at 20,000×g for 1 h at room temperature. The supernatant was 
then loaded into a prepacked HisTrap column (GE Health-
care). The resin was washed with 10 column volume of lysis 
buffer without protease inhibitor and DNAse. The proteins 
were eluted with 20 mM Hepes pH 7.6, 100 mM  Na2SO4, 
500 mM imidazole, 10 mM BME and 10% glycerol. The 
eluted proteins were loaded into a gel filtration Econo-Pac 
10DG column (Biorad) equilibrated with 20 mM Hepes 
buffer pH 7.6, 100 mM  Na2SO4, 10 mM BME, 10% glycerol. 
The protein were eluted using the same buffer and were con-
centrated by using 20 mL spinning Vivaspin 20 filters with a 
10 kDa cut-off (Sartorius AG) to a concentration of 10 mg/mL. 
The proteins were either snap frozen and stored at − 80 °C or 
incubated with 1 unit of thrombin (Calbiochem) per mg of 
protein overnight at room temperature to remove the His-tag. 
The cleaved Fyn SH3–SH2 was separated from the tag by 
gel-filtration using a Superdex75 16/90 column (GE Health-
care) in 50 mM sodium phosphate buffer pH 6.5, 100 mM 
 Na2SO4, 2 mM BME. The fractions containing the protein 
were concentrated using a Vivaspin 20 filter with a 10 kDa 
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cut-off (Sartorius AG). SDS-PAGE was used to determine the 
purity of the sample.
NMR spectroscopy
The concentration of partially deuterated 15N/13C sample of 
Fyn SH3–SH2 used for assignment was 0.7 mM in 50 mM 
sodium phosphate buffer pH 6.5, 100 mM  Na2SO4, 2 mM 
BME, 10%  D2O. NMR data were acquired at 25 °C on a 
Varian Direct-Drive System 600 MHz and an Avance III 
HD Bruker 700 MHz spectrometers, both equipped with a 
cryoprobe. Sequential assignments of the protein were car-
ried out using 15N-HSQC, 13C-HSQC, HNCO, HNCA, 
HNCACB, following classical procedures Side-chains 
assignments were carried out using trosy-HBHANH, trosy-
HBHA(CO)NH, HCCH-TOCSY,  [1H,15N]-HSQC NOESY 
and  [1H,13C]-HSQC NOESY. Backbone assignments were 
obtained using 2D 15N-HSQC, 13C-HSQC, 3D 15N and 13C 
NOESY-HSQC (mixing time: 100 ms) and triple-resonance 
experiments CBCACONH, HNCACB, HCCH-TOCSY, 
HBHANH, HBHACONH. 1D 1H-detected 15N-edited relaxa-
tion experiments were used to calculate the average 15N  T1 and 
 T2 relaxation by fitting the integrated signal in the backbone 
amide 1H region of the spectrum (10.5–8.5 ppm) as a function 
of delay time to an exponential decay. 15N  T1 and  T2 spec-
tra were acquired with a recycle delay of 8.0 s.  T1 relaxation 
delays of 100, 200, 300, 400, 600, 800, 1000, 1500, 2000, 
3000 and 5000 ms and  T2 relaxation delays of 10, 30, 50, 70, 
90, 110, 130, 150, 170 ms were used for data collection. At 
high magnetic field (above 500 MHz), the correlation time 
of a molecule (τC) can be estimated for a rigid protein with 
τC > > 0.5 ns as a function of the ratio of the longitudinal  (T1) 
and transverse  (T2) 15N relaxation times. By considering J(0) 
and J(ωN) spectral density terms and neglecting higher fre-
quency terms, the correlation time of a molecule can be esti-
mated using the following equation: 
where νN is the 15N resonance frequency (in Hz) (Kay et al. 
1989).
All 3D experiments were acquired using non-uniform 
sampling. All NMR spectra were processed using NMRPipe 
(Delaglio et al. 1995) or Bruker’s Topspin 3.2™ and analysed 
by NMRVIEW and CCPNMR (Johnson and Blevins 1994; 
Vranken et al. 2005).
τ
C
≈
1
4πν
N
√
6
T1
T2
− 7,
Assignment and data deposition
Analysis of Fyn SH3–SH2 domain 1D 1H-detected 
15N-edited relaxation experiments in solution showed 
a direct relation between the protein correlation time 
(τC) with its concentration, suggesting that the protein 
under the conditions of the NMR experiments is a mono-
mer–dimer mixture (Fig. 1a) (Rossi et al. 2010). The cor-
relation time of a monomeric protein in solution in nano-
seconds is approximately 0.6 times its molecular weight in 
kDa. For Fyn SH3–SH2, τC is estimated to be 11.8 ns. At 
classical sample concentration for NMR structure deter-
mination (> 0.6 mM), the τc for Fyn SH3–SH2 is above 
16.5  ns. The quality of HSQC spectra decreases with 
incremental concentrations (Fig. 1b) and as a consequence, 
use of uniformly-labeled 15N/13C sample yielded no signal 
in all 3D experiments (Fig. 1c).
Nietlispach et al. showed that 50–60% random frac-
tional deuteration increases the sensitivity of the NMR 
experiments due to the reduction of  R2 of the molecule, 
allowing structure determination by NMR using 15N and 
13C NOESY-HSQC (Nietlispach et al. 1996). Using this 
methodology on the Fyn SH3–SH2 domain, we observed a 
significant improvement on the quality of the NMR spectra 
(Fig. 1d). Using this approach with a 50% deuterated uni-
formly-labeled 15N and 13C Fyn SH3–SH2 resulted in 97% 
of the backbone and 94% of all 1H side chains assignment. 
Due to the random nature of the deuteration processes, the 
chemical shifts were not corrected for 2H isotopes shifts. 
The 15N-HSQC spectrum and assignment are displayed in 
Fig. 2a. The 1H, 13C and 15N chemical shifts were depos-
ited into the BioMagResBank database (http://www.brmb.
wisc.edu/) accession number 27165.
To determine the percentage of monomer/dimer com-
plexes, we performed an analysis of 1D 15N  T1/T2 at 
50–2000  μM concentrations (Fig.  1a). The estimated 
 KD was calculated at 500 and 600 mM, suggesting that 
more than 60% of Fyn SH2–SH3 exists as a dimer at 
0.7 mM. For maintenance of dominant monomeric FYN—
SH3–SH2 in solution, lower concentrations (0.1–0.2 mM) 
are necessary; however, such experimental prerequisites 
hinder spectral assignment and structure determination 
due to lack of signal.
Increasing sample concentrations above 1 mM also 
resulted in loss of NMR signal (broadened peaks; Fig. 1b). 
Dimer formation favoured by higher sample concentra-
tions exhibited as broadened peaks with the exception of 
one peak (R96), which slightly shifted without creating 
ambiguity for its assignment. Analysis of this chemical 
shift perturbation enabled  KD determination in the range 
of 500–700 mM. Thus a concentration of 0.7 mM was 
subsequently selected for all the experiments in this study.
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The chemical shift index (CSI) function and DANGLE 
(Cheung et al. 2010) modules in CCPNMR were used to 
predict the secondary structure of Fyn SH3–SH2 from 
backbone chemical shifts (Fig. 2b). The predicted second-
ary structure is an arrangement of 6 β-strands for the SH3 
domain and 5 β-strands and 2 α-helices for SH2 domain, 
with a short α-helix in the linker between the two domains. 
These data further corroborate previous reports on the 
structure of SH2 and SH3, as a β-sandwich consisting of six 
strands flanked by 2 α-helices and connected by three loops 
and a β-sandwich consisting of five strands flanked by three 
loops and a short  310 helix, respectively (Xu et al. 1999).
The structure of Fyn SH2 free in solution and in com-
plex with the phosphorylated tail of the protein has been 
solved recently (Huculeci et al. 2016). We compared the 
15N HSQC spectrum of the SH3–SH2 domain with the 
single SH2 domain under identical conditions to investi-
gate if there is an effect of the SH3 domain on the struc-
ture of SH2 domain. We observed the expected changes in 
the N-terminal region, but also throughout the sequence 
(Fig.  1e) suggesting a change in the structure of the 
SH2 domain when linked to the SH3 domain. A similar 
experiment using the free SH3 domain resulted in similar 
changes in the SH2 domain, with some still present, espe-
cially in the loop area between b1 et b2 (Fig. 1f). These 
data underline the importance of studying these domains 
within the context of the tandem SH2–SH3 domain or even 
the full-length protein, as these differences may have an 
impact on the potential sidechain-induced communication 
between different parts of a protein.
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Fig. 1  Effect of protein concentration and deuteration on the NMR 
experiment and structural differences between Fyn SH3–SH2 and 
Fyn single domains SH2 and SH3. Plot of Fyn SH2–SH3 correla-
tion time (τC) in function of protein concentration (a). Overlay of 15N-HSQCs of the Fyn SH3–SH2 domain collected at different pro-
tein concentrations (b) (black: 50  μM; gray: 100  μM; light blue: 
200  μM; dark blue: 400  μM; red: 600  μM; green: 900  μ; purple: 
1.5  mM and dark green: 2  mM). 2D 1H/13C projection of the 3D 
HNCACB for a deuteration level of 0% (c) and 50% (d). 15N-HSQC 
overlay spectra of Fyn SH3–SH2 domain (black) in the presence of 
the His tagged Fyn SH2 (e) and SH3 (f) domains (red). Residues 
affected by the presence of the tandem domains have been labeled
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b Threshold deviation from random coil 13CO, 13Cα and 13Cβ were 
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